Lexicon Pharmaceuticals Stock Price, News & Analysis (NASDAQ:LXRX)

$7.86 -0.07 (-0.88 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$7.93
Today's Range$7.81 - $8.04
52-Week Range$7.80 - $18.00
Volume738,400 shs
Average Volume621,912 shs
Market Capitalization$829.92 million
P/E Ratio-6.24
Dividend YieldN/A
Beta0.24

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LXRX
CUSIP52887210
Phone281-863-3000

Debt

Debt-to-Equity Ratio1.09%
Current Ratio1.66%
Quick Ratio1.65%

Price-To-Earnings

Trailing P/E Ratio-6.23809523809524
Forward P/E Ratio-5.70
P/E GrowthN/A

Sales & Book Value

Annual Sales$83.34 million
Price / Sales9.96
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book5.21

Profitability

Trailing EPS($1.26)
Net Income$-141,420,000.00
Net Margins-165.69%
Return on Equity-111.68%
Return on Assets-34.02%

Miscellaneous

Employees168
Outstanding Shares105,590,000

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.07. The biopharmaceutical company earned $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. Lexicon Pharmaceuticals's revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.35) EPS. View Lexicon Pharmaceuticals' Earnings History.

When will Lexicon Pharmaceuticals make its next earnings announcement?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Lexicon Pharmaceuticals.

Where is Lexicon Pharmaceuticals' stock going? Where will Lexicon Pharmaceuticals' stock price be in 2018?

6 brokerages have issued 12-month price targets for Lexicon Pharmaceuticals' shares. Their predictions range from $10.00 to $38.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $24.80 in the next twelve months. View Analyst Ratings for Lexicon Pharmaceuticals.

What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (2/13/2018)
  • 2. Wedbush analysts commented, "Management announced the initiation of its second global Phase 2/3 clinical trial for Plinabulin (for the prevention of chemotherapy-induced neutropenia CIN). Study 106, initiated in China, is enrolling patients who receive TAC (taxotere, doxorubicin and cyclophosphamide) chemotherapy, which often results in severe neutropenia, to demonstrate Plinabulin’s superiority compared with Neulasta, a G-CSF." (11/30/2017)
  • 3. Cowen Inc analysts commented, "Xermelo’s US launch is off to a solid start with 2Q sales of $3.6MM just ahead of." (8/1/2017)
  • 4. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)

Who are some of Lexicon Pharmaceuticals' key competitors?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:

  • Raymond Debbane, Independent Chairman of the Board (Age 62)
  • Lonnel Coats, President, Chief Executive Officer, Director (Age 52)
  • Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs (Age 52)
  • Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer (Age 53)
  • Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations (Age 63)
  • Alexander A. Santini, Executive Vice President, Chief Commercial Officer (Age 58)
  • Praveen Tyle, Executive Vice President - Research and Development
  • James F. Tessmer, Vice President - Finance & Accounting (Age 57)
  • Philippe J. Amouyal, Independent Director (Age 58)
  • Samuel L. Barker Ph.D., Independent Director (Age 74)

Who owns Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Artal Group S.A. (55.19%), BlackRock Inc. (4.13%), Clearbridge LLC (1.13%), Pinnacle Associates Ltd. (0.81%), Deutsche Bank AG (0.52%) and Renaissance Technologies LLC (0.48%). Company insiders that own Lexicon Pharmaceuticals stock include James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Who sold Lexicon Pharmaceuticals stock? Who is selling Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Tocqueville Asset Management L.P., Alliancebernstein L.P., Wells Fargo & Company MN, Pinnacle Associates Ltd., Candriam Luxembourg S.C.A., Metropolitan Life Insurance Co. NY and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Who bought Lexicon Pharmaceuticals stock? Who is buying Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Clearbridge LLC, Tekla Capital Management LLC, Deutsche Bank AG, Renaissance Technologies LLC, Teachers Retirement System of The State of Kentucky, Virtus Fund Advisers LLC and Goldman Sachs Group Inc.. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy Lexicon Pharmaceuticals stock?

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $7.86.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $829.92 million and generates $83.34 million in revenue each year. The biopharmaceutical company earns $-141,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Lexicon Pharmaceuticals employs 168 workers across the globe.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.


MarketBeat Community Rating for Lexicon Pharmaceuticals (LXRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Lexicon Pharmaceuticals (NASDAQ:LXRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.802.802.80
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.80$28.50$28.75$28.75
Price Target Upside: 166.95% upside182.46% upside138.99% upside83.24% upside

Lexicon Pharmaceuticals (NASDAQ:LXRX) Consensus Price Target History

Price Target History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ:LXRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018JPMorgan Chase & Co.DowngradeNeutral -> Underweight$15.00 -> $10.00HighView Rating Details
11/30/2017WedbushReiterated RatingOutperform$38.00MediumView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$21.00MediumView Rating Details
8/1/2017CowenReiterated RatingHoldHighView Rating Details
5/3/2017HC WainwrightSet Price TargetBuy$27.00HighView Rating Details
3/7/2017CitigroupBoost Price TargetBuy$24.00 -> $28.00N/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings History and Estimates Chart

Earnings by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ LXRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.42)N/AView Earnings Details
11/8/2017Q3 2017($0.36)($0.29)$27.97 million$26.94 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.45)($0.33)$18.34 million$12.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.44)($0.33)$14.81 million$18.29 millionViewN/AView Earnings Details
3/3/2017Q4 2016($0.51)($0.31)$15.56 million$23.00 millionViewN/AView Earnings Details
11/1/2016Q316($0.50)($0.35)$9.68 million$27.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.40)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.44 million$0.57 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.05)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details
7/30/2013Q2 2013($0.35)($0.42)$0.28 million$0.21 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.35)($0.35)$0.32 million$0.36 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
7/31/2012Q2 2012($0.42)($0.38)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.49)($0.39)ViewN/AView Earnings Details
2/22/2012Q4 2011($0.56)($0.64)ViewN/AView Earnings Details
11/1/2011Q3 2011($0.63)($0.54)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.63)($0.52)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.49)($0.59)ViewN/AView Earnings Details
2/24/2011Q4 2010($0.56)($0.48)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.56)($0.57)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.49)($0.52)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.49)($0.92)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.98)($0.91)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.98)($0.97)ViewN/AView Earnings Details
7/28/2009Q2 2009($1.12)($1.02)ViewN/AView Earnings Details
4/28/2009Q1 2009($0.91)($1.13)ViewN/AView Earnings Details
2/25/2009Q4 2008($1.19)($0.79)ViewN/AView Earnings Details
10/30/2008Q3 2008($1.12)($1.03)ViewN/AView Earnings Details
7/29/2008Q2 2008($1.12)($1.02)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.84)($0.92)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.91)($0.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Lexicon Pharmaceuticals (NASDAQ:LXRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.28)($0.28)($0.28)
Q4 20181($0.25)($0.25)($0.25)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.77%
Insider Trades by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals (NASDAQ LXRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2017Public Equities L.P. InvusDirectorBuy180,727$10.11$1,827,149.97View SEC Filing  
11/15/2017Lonnel CoatsCEOBuy10,000$9.91$99,100.0042,985View SEC Filing  
11/14/2017Jeffrey L WadeEVPBuy2,000$9.48$18,960.0050,597View SEC Filing  
11/14/2017Public Equities L.P. InvusDirectorBuy575,946$9.64$5,552,119.44View SEC Filing  
11/10/2017Public Equities L.P. InvusDirectorBuy145,680$9.74$1,418,923.20View SEC Filing  
9/15/2017Lonnel CoatsInsiderBuy30,000$12.54$376,200.00View SEC Filing  
9/15/2017Sam L BarkerDirectorBuy1,000$12.50$12,500.0025,623View SEC Filing  
6/6/2016James F TessmerVPSell1,500$15.00$22,500.0017,446View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.0021,946View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/25/2013Bryan A KleinleinCFOSell227,626$0.13$29,591.38View SEC Filing  
10/9/2013Bryan A KleinleinCFOSell83,281$0.19$15,823.39View SEC Filing  
7/9/2013Bryan A KleinleinCFOSell88,235$0.11$9,705.85View SEC Filing  
6/27/2013Alexander Richard WalshCEOSell160,000$0.13$20,800.00View SEC Filing  
6/18/2013Alexander Richard WalshCEOSell220,000$0.18$39,600.00View SEC Filing  
6/7/2013Alexander Richard WalshCEOSell170,000$0.19$32,300.00View SEC Filing  
11/21/2012Alexander Richard WalshCEOSell23,700$0.34$8,058.00View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
10/3/2012Alexander Richard WalshCEOSell25,000$0.30$7,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Lexicon Pharmaceuticals (NASDAQ LXRX) News Headlines

Source:
DateHeadline
Lexicon Pharmaceuticals (LXRX) Stock Rating Upgraded by Zacks Investment ResearchLexicon Pharmaceuticals (LXRX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 19 at 11:58 AM
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast ... - GlobeNewswire (press release)Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast ... - GlobeNewswire (press release)
globenewswire.com - February 17 at 8:11 AM
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018
finance.yahoo.com - February 16 at 8:14 AM
Here's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% TodayHere's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today
finance.yahoo.com - February 14 at 3:43 PM
Heres Why Lexicon Pharmaceuticals Dropped as Much as 13.6% TodayHere's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today
www.fool.com - February 14 at 3:20 PM
Lexicon Pharmaceuticals (LXRX) Cut to Underweight at JPMorgan Chase & Co.Lexicon Pharmaceuticals (LXRX) Cut to Underweight at JPMorgan Chase & Co.
www.americanbankingnews.com - February 14 at 10:38 AM
$29.80 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter$29.80 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - February 13 at 4:32 AM
Lexicon Pharmaceuticals (LXRX) Downgraded by BidaskClubLexicon Pharmaceuticals (LXRX) Downgraded by BidaskClub
www.americanbankingnews.com - February 5 at 11:58 PM
Lexicon Pharmaceuticals (LXRX) Downgraded by ValuEngineLexicon Pharmaceuticals (LXRX) Downgraded by ValuEngine
www.americanbankingnews.com - February 4 at 11:22 PM
Lexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from BrokeragesLexicon Pharmaceuticals, Inc. (LXRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 2 at 3:15 AM
-$0.43 EPS Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter-$0.43 EPS Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - January 25 at 11:34 AM
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street - Yahoo Finance3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street - Yahoo Finance
finance.yahoo.com - January 22 at 6:34 AM
Lexicon Pharmaceuticals (LXRX) Rating Increased to Sell at BidaskClubLexicon Pharmaceuticals (LXRX) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - January 20 at 9:48 AM
Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) Will Announce Quarterly Sales of $29.80 MillionZacks: Analysts Expect Lexicon Pharmaceuticals, Inc. (LXRX) Will Announce Quarterly Sales of $29.80 Million
www.americanbankingnews.com - January 10 at 4:30 PM
Zacks: Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) to Announce -$0.43 Earnings Per ShareZacks: Analysts Anticipate Lexicon Pharmaceuticals, Inc. (LXRX) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - January 8 at 9:40 AM
Lexicon Pharmaceuticals, Inc. (LXRX) Receives Average Recommendation of "Hold" from AnalystsLexicon Pharmaceuticals, Inc. (LXRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 8 at 4:36 AM
Lexicon Pharmaceuticals Announces Poster Presentation at ASCO GILexicon Pharmaceuticals Announces Poster Presentation at ASCO GI
finance.yahoo.com - January 2 at 5:57 PM
Lexicon Pharmaceuticals to Present at Upcoming Investor ConferenceLexicon Pharmaceuticals to Present at Upcoming Investor Conference
finance.yahoo.com - January 2 at 9:30 AM
Lexicon Pharmaceuticals (LXRX) Downgraded to "Strong Sell" at ValuEngineLexicon Pharmaceuticals (LXRX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - January 1 at 6:04 PM
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : January 1, 2018Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : January 1, 2018
finance.yahoo.com - January 1 at 9:29 AM
Lexicon Pharmaceuticals (LXRX) vs. Its Rivals Head-To-Head ContrastLexicon Pharmaceuticals (LXRX) vs. Its Rivals Head-To-Head Contrast
www.americanbankingnews.com - December 29 at 1:56 AM
ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 1:15 PM
Lexicon Pharmaceuticals (LXRX) & The Competition Critical ContrastLexicon Pharmaceuticals (LXRX) & The Competition Critical Contrast
www.americanbankingnews.com - December 28 at 8:48 AM
Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $29.80 MillionLexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $29.80 Million
www.americanbankingnews.com - December 25 at 11:02 PM
Lexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $29.80 MillionLexicon Pharmaceuticals, Inc. (LXRX) Expected to Announce Quarterly Sales of $29.80 Million
www.americanbankingnews.com - December 25 at 11:02 PM
-$0.43 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter-$0.43 Earnings Per Share Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - December 23 at 1:23 AM
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 22, 2017Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 22, 2017
finance.yahoo.com - December 22 at 9:39 AM
ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 15, 2017ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 5:23 PM
Short Interest in Lexicon Pharmaceuticals, Inc. (LXRX) Decreases By 17.3%Short Interest in Lexicon Pharmaceuticals, Inc. (LXRX) Decreases By 17.3%
www.americanbankingnews.com - December 14 at 4:10 AM
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 11, 2017Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : December 11, 2017
finance.yahoo.com - December 11 at 10:17 AM
Lexicon Pharmaceuticals (LXRX) versus Its Rivals Financial AnalysisLexicon Pharmaceuticals (LXRX) versus Its Rivals Financial Analysis
www.americanbankingnews.com - December 8 at 11:30 PM
ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 5, 2017ETFs with exposure to Lexicon Pharmaceuticals, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 4:53 PM
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing - GlobeNewswire (press release)Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing - GlobeNewswire (press release)
globenewswire.com - December 5 at 10:13 AM
Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan FinancingLexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing
finance.yahoo.com - December 5 at 10:13 AM
FY2017 EPS Estimates for Lexicon Pharmaceuticals, Inc. (LXRX) Boosted by WedbushFY2017 EPS Estimates for Lexicon Pharmaceuticals, Inc. (LXRX) Boosted by Wedbush
www.americanbankingnews.com - December 4 at 1:52 AM
FY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. (LXRX) Issued By WedbushFY2019 Earnings Estimate for Lexicon Pharmaceuticals, Inc. (LXRX) Issued By Wedbush
www.americanbankingnews.com - December 2 at 10:00 AM
Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
finance.yahoo.com - December 1 at 4:53 PM
Lexicon Pharmaceuticals (LXRX) "Outperform" Rating Reaffirmed at WedbushLexicon Pharmaceuticals' (LXRX) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - November 30 at 7:46 AM
Lexicon Pharmaceuticals, Inc. (LXRX) Rating Increased to Hold at Zacks Investment ResearchLexicon Pharmaceuticals, Inc. (LXRX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - November 25 at 10:52 PM
First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)First Week Of July 2018 Options Trading For Lexicon Pharmaceuticals (LXRX)
www.thestreet.com - November 22 at 2:20 AM
Lexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of "Hold" by AnalystsLexicon Pharmaceuticals, Inc. (LXRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 3:44 AM
$26.57 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter$26.57 Million in Sales Expected for Lexicon Pharmaceuticals, Inc. (LXRX) This Quarter
www.americanbankingnews.com - November 18 at 3:56 AM
Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Buys 180,727 Shares of StockInsider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Buys 180,727 Shares of Stock
www.americanbankingnews.com - November 17 at 10:26 PM
Lexicon (LXRX) Looks Good: Stock Adds 7.6% in SessionLexicon (LXRX) Looks Good: Stock Adds 7.6% in Session
finance.yahoo.com - November 17 at 2:37 PM
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Acquires $99,100.00 in StockLexicon Pharmaceuticals, Inc. (LXRX) CEO Acquires $99,100.00 in Stock
www.americanbankingnews.com - November 15 at 9:10 PM
Insider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases 145,680 Shares of StockInsider Buying: Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases 145,680 Shares of Stock
www.americanbankingnews.com - November 14 at 11:03 PM
Lexicon Pharmaceuticals, Inc. (LXRX) Director Public Equities L.P. Invus Buys 575,946 SharesLexicon Pharmaceuticals, Inc. (LXRX) Director Public Equities L.P. Invus Buys 575,946 Shares
www.americanbankingnews.com - November 14 at 10:34 PM
Jeffrey L. Wade Purchases 2,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) StockJeffrey L. Wade Purchases 2,000 Shares of Lexicon Pharmaceuticals, Inc. (LXRX) Stock
www.americanbankingnews.com - November 14 at 9:50 PM
5 greater Houston-area companies make Deloittes Technology Fast 500 - Houston Business Journal5 greater Houston-area companies make Deloitte's Technology Fast 500 - Houston Business Journal
www.bizjournals.com - November 13 at 5:13 PM
Lexicon Pharmaceuticals, Inc. (LXRX) Sees Significant Decrease in Short InterestLexicon Pharmaceuticals, Inc. (LXRX) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - November 12 at 5:34 AM

SEC Filings

Lexicon Pharmaceuticals (NASDAQ:LXRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Lexicon Pharmaceuticals (NASDAQ:LXRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Lexicon Pharmaceuticals (NASDAQ LXRX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.